PharmaShots | Incisive News in 3 Shots

Subscribe Now

ORIC Pharmaceuticals

ORIC Pharmaceuticals Doses First Patients Across Expansion Arms in the P-Ib Study of ORIC-114 for the Treatment of Mutated NSCLC

ORIC Pharmaceuticals Doses First Patients Across Expansion Arms in the P-Ib Study of ORIC-114 for the Treatment of Mutated NSCLC

April 16, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us